β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2

The inhibitors for EGF receptor tyrosine kinase (EGFR-TKIs) such as gefitinib have been used as a standard treatment for non-small cell lung cancer (NSCLC), but the increasingly occurrence of drug resistance, the associated adverse effects and the enrichment of cancer stem cells significantly impede...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Haibo, Ge, Xiaoyin, Zhuo, Shiqin, Gao, Yanan, Zhu, Bo, Zhang, Junfeng, Shang, Wenbin, Xu, Dakang, Ge, Weihong, Shi, Liyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284059/
https://www.ncbi.nlm.nih.gov/pubmed/30555330
http://dx.doi.org/10.3389/fphar.2018.01413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284059/
https://www.ncbi.nlm.nih.gov/pubmed/30555330
http://dx.doi.org/10.3389/fphar.2018.01413

Ejemplares similares